Casdin Capital, LLC
Casdin Capital, LLC reported 43 holdings worth US$2B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Casdin Capital, LLC reported 43 holdings worth US$2B as of Jun 30, 2026. Largest: Revolution Medicines, Inc., Relay Therapeutics, Inc. and Genedx Holdings Corp. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 43
- Value as reported
- US$2B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Revolution Medicines, Inc. | 2.58M | US$483M | 24.2% |
| Relay Therapeutics, Inc. | 16M | US$300M | 15.0% |
| Genedx Holdings Corp. | 3.71M | US$254M | 12.7% |
| Biolife Solutions, Inc. | 4.66M | US$131M | 6.6% |
| Illumina, Inc. | 530K | US$93.2M | 4.7% |
| Standard Biotools Inc. | 88.8M | US$73M | 3.7% |
| Denali Therapeutics Inc. | 2.04M | US$52.6M | 2.6% |
| Neurogene Inc. | 1.55M | US$48.6M | 2.4% |
| Beam Therapeutics Inc. | 1.35M | US$46.3M | 2.3% |
| 10x Genomics, Inc. | 1.05M | US$40.3M | 2.0% |
| Scholar Rock Holding Corporation | 665K | US$36.6M | 1.8% |
| Personalis, Inc. | 2.55M | US$34.2M | 1.7% |
| Grail, Inc. | 480K | US$32.8M | 1.6% |
| Guardant Health, Inc. | 185K | US$27.8M | 1.4% |
| Maze Therapeutics, Inc. | 844K | US$25.2M | 1.3% |
| Hims & Hers Health, Inc. | 700K | US$24.3M | 1.2% |
| Alnylam Pharmaceuticals, Inc. | 75,000 | US$22.6M | 1.1% |
| Taysha Gene Therapies, Inc. | 3.25M | US$22.1M | 1.1% |
| Septerna, Inc. | 553K | US$18.5M | 0.93% |
| Parabilis Medicines, Inc. | 646K | US$17.7M | 0.88% |
| Sionna Therapeutics, Inc. | 400K | US$17.6M | 0.88% |
| Veracyte, Inc. | 276K | US$16.2M | 0.81% |
| Prime Medicine, Inc. | 3.17M | US$11.7M | 0.58% |
| Absci Corporation | 973K | US$11.3M | 0.56% |
| Quest Diagnostics Incorporated | 50,000 | US$10.6M | 0.53% |
| Sarepta Therapeutics, Inc. | 470K | US$8.45M | 0.42% |
| Intellia Therapeutics, Inc. | 355K | US$6.01M | 0.30% |
| Moderna, Inc. | 75,000 | US$5.25M | 0.26% |
| Disc Medicine, Inc. | 65,000 | US$4.75M | 0.24% |
| Monte Rosa Therapeutics, Inc. | 186K | US$4.5M | 0.23% |
| Century Therapeutics, Inc. | 1.23M | US$3.01M | 0.15% |
| Contineum Therapeutics, Inc. | 148K | US$2.43M | 0.12% |
| Bridgebio Oncology Therapeutics, Inc. | 282K | US$2.15M | 0.11% |
| Editas Medicine, Inc. | 445K | US$1.44M | 0.07% |
| Pacific Biosciences Of California, Inc. | 724K | US$1.22M | 0.06% |
| Kardigan, Inc. | 50,000 | US$1.19M | 0.06% |
| Recursion Pharmaceuticals, Inc. | 165K | US$607K | 0.03% |
| Ginkgo Bioworks Holdings, Inc. | 36,493 | US$362K | 0.02% |
| Tenaya Therapeutics, Inc. | 362K | US$268K | 0.01% |
| Tempus Ai, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related